As of 31 August 2018, UBS has sold the hotel Widder as well as adjacent premises located at Augustinerhof 1, Augustinergasse 15 and 20 as well as Widdergasse 10, to Swiss Life. The sale is a consequence of the upcoming re-opening of UBS's headquarter at Bahnhofstrasse 45 which will create additional space for UBS which is why the hotel Widder will no longer be required as a alternate location for conferences and seminars.
London—Dentons has advised Bilby Plc ("the Group"), the AIM-listed gas heating, electrical and building services provider, on the share sale by its founder and Deputy Chairman, Phil Copolo, following his decision to retire from the business and resign from the Board.
International law firm Pinsent Masons is advising Cambridge-based biopharmaceutical services company Abzena plc on its recommended acquisition by a fund set up by US private equity house Welsh, Carson, Anderson & Stowe.
Astro Bidco Limited, which is wholly-owned by the WCAS Fund, has offered to pay Abzena shareholders 16p per share. Under the terms of the acquisition, the deal is valued at approximately £34.4 million on a fully diluted basis.
De Brauw has advised De Volksbank on the divestment of ASN Vermogesbeheer.
Client name
De Volksbank N.V.
Other parties involved
Fair Capital Partners B.V.
Nature of transaction
De Volksbank reached agreement for the sale of 100% of the shares in ASN Vermogensbeer B.V.
Value of transaction
Undisclosed
Date deal
31 August 2018
De Brauw involvement
Legal counsel to De Volksbank
Other advisors
- Orange Clover
De Brauw lead partner
Anja Mutsaers
PARIS – Dechert LLP advised the shareholders of NHCO Nutrition, a France-based company specializing in dietary supplements distributed in drugstores, on the sale of 100% of its share capital to Chiesi, an international research-oriented healthcare group.
Focusing on research and innovation in the field of nutrition sciences and Aminoscience (amino acid science), NHCO Nutrition is among the leading players in the world of dietary supplements thanks to its strategy of product differentiation and its commercial approach to customer services.
International law firm Ashurst is advising Goldman Sachs and Morgan Stanley as joint sponsors to Whitbread in relation to its proposed sale of Costa to The Coca-Cola Company for an enterprise value of £3.9 billion, announced today.
The proposed sale is a Class 1 transaction for Whitbread under the Listing Rules and is therefore conditional, among other matters, upon the approval of shareholders. Completion of the transaction is expected during the first half of 2019.
Slaughter and May is advising Whitbread PLC ("Whitbread") on its sale of Costa Limited (“Costa”) to The Coca-Cola Company ("Coca-Cola") for an enterprise value of £3.9 billion.
Costa is a leading international coffee brand, with over 2,400 coffee shops in the UK and over 1,400 stores in more than 30 international markets. Coca-Cola is a total beverage company, offering over 500 brands in more than 200 countries and territories.
Paris – Paul Hastings LLP, a leading global law firm, announced today that it has advised the shareholders of Skill & You (21 Centrale Partners, Access Capital Partners, Jolt Capital, Alma Learning Group, and Capital Transmission and the management team led by Eric Petco and Sonia Levy-Odier) in connection with the LBO of the group by Andera Partners, alongside Omnes Capital as minority co-investor. LGT European Capital has provided a unitranche financing to support this acquisition.
International legal practice Osborne Clarke has advised the management team of MThree Corporate Consulting Limited (MThree) on the investment by ECI Partners in MThree. The company will continue to be led by founder and CEO, Alex Headley.
Matheson recently advised San Diego based Zavante Therapeutics on its acquisition by Irish registered, NASDAQ listed, Nabriva Therapeutics plc. in a deal that involved the issuance of upfront consideration in the form of Nabriva shares.
Nabriva is a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections.
Zavante is a biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients.